Full-Time

Manager/Senior Manager

SEC Reporting and Technical Accounting

Posted on 9/11/2025

Coherus BioSciences

Coherus BioSciences

201-500 employees

Develops and commercializes biosimilar biologics

Compensation Overview

$115k - $175k/yr

San Carlos, CA, USA

In Person

Location specified as Redwood City, California. No mention of remote or hybrid. Company offices in multiple locations not relevant.

Category
Accounting (3)
, ,
Required Skills
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in accounting.
  • Minimum of 6-9 years of recent accounting experience required, including at least four years of SEC reporting experience.
  • Big 4 experience required.
  • Toppan Merrill Bridge experience preferred.
  • Certified Public Accountant designation preferred.
  • Proficient knowledge of U.S. GAAP
  • Proficient with Excel required (pivot tables, vlookup, SUMIF, etc.)
Responsibilities
  • Prepare quarterly and annual SEC filings on Form 10-Q and Form 10-K
  • Compile financial statements (consolidated balance sheet, consolidated income statement, statement of cash flows, statement of stockholders’ equity, footnotes), management disclosures and analysis and other SEC disclosures.
  • Prepare EPS calculations.
  • Prepare disclosure checklists.
  • Ensure financial statements are prepared in accordance with US GAAP and SEC regulations, including newly issued accounting pronouncements.
  • Review and approve XBRL tagging of financial statements under US GAAP.
  • Manage internal and external review for these documents.
  • Prepare quarterly earnings release tables.
  • Determine and manage timelines for financial statement preparation and filing and work collaboratively with various business partners to ensure such timelines are met.
  • Prepare necessary documents for the company’s disclosure committee on a timely basis.
  • Perform technical accounting research and prepare technical memoranda.
  • Manage third-party resources if utilizing their services to assist in technical accounting research.
  • Implement new accounting standards and practices.
  • Recommend, implement, maintain, and communicate accounting policies, practices and procedures to ensure the integrity of the company’s financial statements.
  • Prepare audit schedules and respond to auditor inquiries.
  • Assist with quarterly flux analysis.
  • Assist with overall company-wide SOX compliance.
  • Prepare Debt, Lease and other technical journal entries and account reconciliations.
  • Assist with consolidation and financial close activities.
  • Manage and complete special projects as necessary.
Desired Qualifications
  • Toppan Merrill Bridge experience preferred.
  • Certified Public Accountant designation preferred.
  • Proficient knowledge of U.S. GAAP
  • Big 4 experience required.
  • Proficient with Excel required (pivot tables, vlookup, SUMIF, etc.)

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines. These products are created through biotechnology to match the safety and effectiveness of the original biologics while offering lower prices. Coherus’ products are designed to provide patients and healthcare systems with more affordable access to essential biologic treatments and to offset rising healthcare costs. The company differentiates itself by focusing on high-quality biosimilars and a rigorous regulatory pathway to ensure similar efficacy and safety to the originals, enabling broader adoption among providers, hospitals, and patients. Its goal is to improve patient lives by expanding access to life-changing biologic medicines and making treatments more affordable.

Company Size

201-500

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • LOQTORZI revenue doubled to $40.8M in 2025, targeting $175M run-rate by 2028.
  • Debt slashed 90% from $480M to $38.8M, saving $15M annual interest.
  • $50M raised February 2026 funds LOQTORZI commercialization and pipeline.

What critics are saying

  • Commercial chief exit stalls LOQTORZI Q1 2026 sales ramp to $15M quarterly.
  • Apotex deal transfers Canadian toripalimab rights, eroding North American revenue.
  • Keytruda dominance caps LOQTORZI below $30M quarterly breakeven in 18 months.

What makes Coherus BioSciences unique

  • Pioneers next-generation PD-1 inhibitor LOQTORZI for nasopharyngeal carcinoma.
  • Advances Tagmokitug anti-CCR8 and casdozokitug IL-27 antibodies in oncology pipeline.
  • Transforms from biosimilars to innovative immuno-oncology combination therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive base salary

Target bonus based on performance

stock options

Medical, dental, & vision coverage

PTO

401(k) plan

FSA

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 10th, 2026
Coherus Oncology doubles LOQTORZI revenue to $41M, slashes debt by 90% to $39M

Coherus Oncology has reported strong revenue growth for 2025, with its drug LOQTORZI achieving net revenue of $40.8 million, a 113% increase from $19.1 million in 2024. Fourth-quarter revenue reached $12.4 million, marking an 11% growth over the third quarter. The company significantly improved its financial position by reducing debt by over 90%, from $480 million to $38.8 million by year-end 2025. This resulted in interest cost savings of over $15 million. The firm also cut headcount by 35% and reduced selling, general and administrative expenses to $23.6 million in Q4 from $29.6 million the previous year. Coherus ended 2025 with $172.1 million in cash and investments whilst developing two promising product candidates, Tagmokitug and casdozokitug.

Yahoo Finance
Mar 8th, 2026
Coherus cuts debt 90%, LOQTORZI sales double in 2025, eyes $175M annual run rate by 2028

Coherus Oncology has reduced its debt by approximately 90%, cutting it from $480 million to $3.7 million in senior secured debt, whilst adding $250 million to its balance sheet through biosimilar asset divestitures following its 2023 Surface Oncology acquisition. The company reported accelerating sales of LOQTORZI, its PD-1 therapy for nasopharyngeal carcinoma, with 2025 sales doubling from 2024's $19 million. Management expects quarterly sales to reach $15 million to $16 million in 2026, covering the commercial team's costs, and projects a long-term run rate of roughly $175 million annually by 2028. Coherus aims to achieve cash-flow breakeven, excluding clinical trial costs, when quarterly sales exceed $30 million. The company has scheduled clinical data readouts for two pipeline assets in 2026.

MarketScreener
Feb 13th, 2026
Coherus Oncology prices $50M public offering at $1.75 per share to fund LOQTORZI commercialisation

Coherus Oncology has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share. The company expects to raise approximately $50.1 million in gross proceeds before underwriting discounts and expenses. The offering includes a 30-day option for underwriters to purchase an additional 4.29 million shares. The transaction is expected to close on 17 February 2026. Coherus plans to use the net proceeds to support commercialisation of LOQTORZI, continue clinical development of product candidates, and for working capital and general corporate purposes. The commercial-stage oncology company has an approved PD-1 inhibitor and a pipeline targeting liver, prostate, head and neck, and colorectal cancers. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners.

Coherus Oncology
Jan 6th, 2026
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Coherus management to present at the 44th Annual J.P. Morgan Healthcare Conference. REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) - Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until February 13, 2026. About Coherus Oncology Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI(R)(toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, colorectal and other cancers. The Company's strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations. Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma. For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.

PharmiWeb.com
May 28th, 2025
Storm Therapeutics Announces First Patient Dosed In Clinical Collaboration To Evaluate Stc-15 In Combination With Loqtorzi® And Appointment Of Atif Abbas, M.D., As Chief Medical Officer

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer. STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor

INACTIVE